Critical Review: Anteris Technologies Global (NASDAQ:AVR) & ClearPoint Neuro (NASDAQ:CLPT)

Anteris Technologies Global (NASDAQ:AVR) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Valuation and Earnings

This table compares Anteris Technologies Global and ClearPoint Neuro”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$2.70 million	61.03	-$76.29 million	N/A	N/A
ClearPoint Neuro	$31.39 million	23.58	-$18.91 million	($0.81)	-32.14

ClearPoint Neuro has higher revenue and earnings than Anteris Technologies Global.

Analyst Ratings

This is a summary of recent ratings and price targets for Anteris Technologies Global and ClearPoint Neuro, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1	0	4	0	2.60
ClearPoint Neuro	1	0	3	0	2.50

Anteris Technologies Global currently has a consensus price target of $16.50, indicating a potential upside of 261.05%. ClearPoint Neuro has a consensus price target of $19.67, indicating a potential downside of 24.45%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Anteris Technologies Global is more favorable than ClearPoint Neuro.

Profitability

This table compares Anteris Technologies Global and ClearPoint Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	N/A	N/A	N/A
ClearPoint Neuro	-66.15%	-94.44%	-51.58%

Institutional and Insider Ownership

30.1% of ClearPoint Neuro shares are held by institutional investors. 4.0% of Anteris Technologies Global shares are held by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Anteris Technologies Global beats ClearPoint Neuro on 7 of the 11 factors compared between the two stocks.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.